ReadyRx Review
Best for: compounded GLP-1 buyers who want LegitScript certification and explicit batch lab testing claims at a sub-$200 starting price
ReadyRx (readyrx.com) is a LegitScript-certified US telehealth provider offering compounded semaglutide from $179/mo and compounded tirzepatide from $255/mo, plus NAD+, sermorelin, glutathione, MIC+B12, and metformin. Marketed as serving 5,000+ members across all 50 states with batch lab testing for potency, sterility, pH, and endotoxicity.
Medium confidence · Last verified 2026-04-09 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
ReadyRx is a solid telehealth option with balanced features and pricing.
Score Breakdown
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Compounded semaglutide (starting) | compounded | $179 |
| Compounded tirzepatide (starting) | compounded | $255 |
✓ Pros
- •LegitScript certified — directly verifiable via the badge link in the footer
- •Batch lab testing claim covers four standard QA categories (potency, sterility, pH, endotoxicity) — these are the right metrics for compounded injectables
- •Pricing publicly displayed: $179/mo semaglutide, $255/mo tirzepatide
✗ Cons
- •Specific FDA-registered pharmacy partner names are not disclosed publicly — claim is generic ('FDA-registered compounding pharmacies')
- •Clinical staff are described as 'Licensed, board-certified clinicians' but no individual NPIs or names are published on the homepage
- •5,000+ member figure is sourced from a competitor directory, not independently audited
Ready to start with ReadyRx?
Starting at $179/month. See current pricing and start your free consultation.
Sources & methodology
Our ReadyRx review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of April 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to ReadyRx
Editorial score · methodology
Editorial score · methodology
Alloy
Best for: women in menopause/perimenopause who want a Menopause Society-certified clinician AND the broadest brand+compounded GLP-1 formulary in our directory
Editorial score · methodology
Frequently Asked Questions
Ready to start with ReadyRx?
Starting at $179/month. See current pricing and start your free consultation.